NAFDAC Director-General, Mojisola Adeyeye, has attributed the persistence of counterfeit and substandard medicines in Nigeria to decades of regulatory gaps, specifically noting historical challenges in managing patent medicine dealers and the proliferation of open drug markets. Amidst mounting public scrutiny over fake consumer goods, Adeyeye defended the agency’s enforcement record, highlighting that over 7,200 products were removed from circulation between May and July 2026. The agency has secured 64 convictions for counterfeiting offenses during this period, with prison sentences ranging from one to seven years. NAFDAC emphasized that addressing the issue requires sustained, long-term regulatory reform and adherence to international standards, such as the Common Technical Document for drug registration, rather than short-term interventions. Furthermore, the agency urged the public to report suspected products through official channels instead of relying on unverified social media narratives, while clarifying the limits of its mandate regarding fresh agricultural produce and unbranded traditional foodstuffs.